


PHARMACEUTICAL 2020

CTI BIOPHARMA CORP Rank 266 of 362







PHARMACEUTICAL 2020

CTI BIOPHARMA CORP Rank 266 of 362



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 38% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Net Income, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -390%, being 87% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	35,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,488
Liabilities, Non-Current	9,862
Other Assets	9,465
Other Compr. Net Income	-1,347
Other Expenses	794
Other Liabilities	0
Other Net Income	688
Property and Equipment	1,235
Research and Development	24,107
Revenues	3,345
Selling, General and Administrative Expense	19,155

Output Variable	Value in 1000 USD
Assets	46,280
Liabilities	28,350
Expenses	44,056
Stockholders Equity	17,930
Net Income	-40,023
Comprehensive Net Income	-40,696
Economic Capital Ratio	-390%